Last updated: June 7, 2026
Orforglipron calcium suppliers: contract manufacturers, API sources, and formulation partners
Orforglipron calcium is still in active development and early-market commercialization planning, so supplier and manufacturing assignments are concentrated in a limited set of CDMOs and raw-material channels rather than a broad, widely disclosed vendor roster. The only reliably actionable supplier information that can be stated without risking incorrect attribution is that the drug’s supply chain is organized through contract manufacturing and analytical services tied to the program’s sponsoring companies and their manufacturing networks, with final drug product typically produced by a CDMO under quality agreements and tech transfer from the rights holder.
No other complete supplier-by-supplier list (API manufacturers, drug-product CDMOs, excipient suppliers, and packaging vendors) can be provided from the available information stream without introducing attribution errors.
What manufacturers make orforglipron calcium API and drug product?
Answer: Supplier visibility is limited to program-linked manufacturing networks disclosed in regulatory filings and sponsor communications, not a fully public, vendor-by-vendor list.
API manufacturing (active ingredient)
- Orforglipron calcium API is typically produced under commercial manufacturing orders by a specialized chemical manufacturer or CDMO with peptide/small-molecule development capability, GMP analytical release, and controlled substance or high-potency handling if applicable.
- Public disclosure rarely names the API site in marketing materials. Site names often surface only in 2020s-era NDA/BLA or CTA-quality sections, and those are not uniformly public in a vendor list format.
Drug product manufacturing (tablets/capsules/salts)
- Drug product is typically produced by an experienced solid-dose CDMO using a tech-transferred process, with salt formation controls for “calcium” spec targets (particle size, polymorph, hydration state, residual solvents).
- Final fill-finish and packaging vendors are usually identified only in manufacturing change notifications or GMP documentation, not in a consumer-accessible supplier roster.
Which CDMOs support orforglipron calcium formulations and scale-up?
Answer: The CDMO roster is not fully public as a complete list, and assigning specific named vendors without primary-source confirmation risks misidentification.
Formulation workstreams CDMOs typically cover
- Salt characterization and stability program aligned to calcium salt specs
- Solid oral dose development (dose uniformity, dissolution, and hygroscopicity control)
- Scale-up of granulation, tableting, and coating processes
- Stability chambers and accelerated/long-term protocols
Analytical and release testing partners
- Method development and validation (HPLC/UPLC, LC-MS, impurity profiling)
- Salt form and polymorph identification (XRPD/DSC as applicable)
- Content uniformity and dissolution test method qualification
Are there specific orforglipron calcium suppliers by geography (US, EU, China)?
Answer: Regional supplier mapping is generally driven by where clinical supply is produced and where the sponsor files CMC dossiers. A full geography-by-geography list is not reliably enumerable from public disclosures.
- US commercialization supply often concentrates at FDA-inspected GMP sites for drug product and at compliant API sites for starting material supply.
- EU supply uses local release and sometimes different packaging lines to meet EU batch-release expectations.
- China supply chains usually cover clinical/comparability batches and intermediate supply, but vendor names are not consistently public.
What’s the Orange Book status of orforglipron calcium, and does it affect supplier sourcing?
Answer: Orange Book status does not directly determine who supplies API or drug product. It governs approved product IP and generic/biosimilar entry timelines, not procurement of excipients or manufacturing sites.
Why the supplier list still matters during IP transitions
- Even under strong IP, manufacturing scale requires secure vendor capacity and redundancy for API and drug product.
- During patent challenges or label expansions, supply chains adjust to maintain GMP compliance and avoid sourcing disruptions.
How do generic entry risks affect orforglipron calcium supplier strategy?
Answer: Supplier diversification typically increases near the end of exclusivity to de-risk manufacturing bottlenecks. That does not require a known vendor roster to state the mechanism: CDMOs qualify multiple lines and redundant materials to keep schedule certainty.
What patent or licensing structure governs who can supply orforglipron calcium?
Answer: Licensing and tech-transfer agreements usually restrict API and drug-product process transfer to qualified manufacturing partners. Those contractual terms, not public vendor lists, determine supplier eligibility.
Typical constraints that limit supplier switching
- Process IP embedded in tech transfer
- Analytical method ownership and controlled references
- Salt formation know-how and impurity control strategies
- Regulatory file reliance on specific validated processes
Competitive landscape: who else could supply orforglipron calcium?
Answer: Competition for manufacturing is usually between CDMOs with the right dosage-form capability and chemistry know-how. Without primary-source disclosures listing named vendors, a complete competitor supplier list cannot be produced correctly.
Key Takeaways
- A fully enumerated supplier roster for orforglipron calcium (named API and drug-product manufacturers, packaging vendors, and excipient sources) is not available in a way that can be reproduced accurately without risking incorrect attributions.
- Practical sourcing is controlled through sponsor-linked manufacturing networks, tech transfer, and GMP quality agreements, rather than a widely public “all vendors” list.
- Supplier strategy is driven by schedule de-risking (API continuity and solid-dose capacity), not by Orange Book status.
FAQs
- What excipients are commonly used in calcium salt solid oral formulations like orforglipron calcium?
- Do API suppliers differ from drug-product CDMOs for orforglipron calcium?
- How long does it typically take to qualify a new CDMO for a calcium salt solid oral product?
- What documentation is required to rely on CMC methods when switching manufacturing sites for orforglipron calcium?
- What are the main quality risks in manufacturing orforglipron calcium (salt form, impurities, dissolution)?
References
- FDA Orange Book. Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book). U.S. Food and Drug Administration. https://www.accessdata.fda.gov/scripts/cder/daf/
- FDA. CMC information in NDA/BLA review context. U.S. Food and Drug Administration. https://www.fda.gov/drugs/development-approval-process-drugs/chemistry-manufacturing-and-controls
